Spots Global Cancer Trial Database for Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia

Official Title: Chemosensitization With Plerixafor Plus G-CSF in Relapsed or Refractory Acute Myeloid Leukemia

Study ID: NCT00906945

Conditions

Leukemia, Myeloid, Acute

Interventions

Study Description

Brief Summary: This study is designed to test the combination of Plerixafor with G-CSF for chemosensitization in patients with relapsed or refractory AML.

Detailed Description: In this study, we are seeking to target the leukemia microenvironment to overcome disease resistance. We hypothesize that by disrupting the interaction of leukemic blasts with the bone marrow microenvironment, we may sensitize leukemic blasts to the effects of cytotoxic chemotherapy. In this study, we seek to maximize blockage of the SDF-1/CXCR4 axis through the following: 1. Addition of G-CSF, which down regulates SDF-1 expression and acts synergistically with plerixafor in stem cell mobilization 2. Intravenous instead of subcutaneous dosing of plerixafor to improve kinetics of administration. 3. Dose escalation of plerixafor and twice daily dosing to maintain maximum CXCR4 blockade.